Evidence Hub

Animal models of cisplatin‐induced neuropathic pain

Ningxin Li, Ming-Zhu Li, Shengbo Jin, Jun Yu, Hongzhe Wei, Wen-Ping Wang, Si-Yao Ma, Yu-Xin Jiang et al.

Animal Models and Experimental Medicine, 2025

2 citations

Abstract

Cisplatin chemotherapy has been used as the main treatment for different types of cancer. However, cisplatin chemotherapy‐induced peripheral neuropathic pain (CIPNP) seriously affects the treatment process and quality of life of patients. In addition, it impacts the underlying mechanism and prevention and treatment strategies, indicating that drug selection and efficacy evaluation need to be further investigated. Furthermore, an animal model that is more consistent with the pathological mechanism needs to be developed. In this study, we describe and discuss the methods of developing and detecting CIPNP models in rats and mice induced by cisplatin chemotherapy. The aim was to improve the modeling rate and develop animal models that are more consistent with the developmental pattern of the disease. In addition, the study provides ideal reference animal models for clinical research and drug discovery and development.

How strong is the evidence?

Evidence Hub reads this as a review, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free